OpenAlex
PricingAboutJobs
Log inGet started
Work

A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation

HTML

Year: 2016
Type: article
Source: Molecular Cancer Therapeutics
DOI: 10.1158/1535-7163.mct-15-0617
Authors: Irene C. Waizenegger, Anke Baum, Steffen Steurer, Heinz Stadtmüller, Gerd Bader, Otmar Schaaf, Pilar Garin-Chesa, Andreas Schlattl, Norbert Schweifer, Christian Haslinger, Florian Colbatzky, Sien Mousa, Arno Kalkuhl, Norbert Kraut, Günther R. Adolf
Institutions: Boehringer Ingelheim (Austria), Boehringer Ingelheim (Germany)
Language: English

Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: Raf kinase inhibitor, DFG-out conformation, BRAF-mutant melanoma, vemurafenib, trametinib, drug resistance, vemurafenib resistance, combination therapy, therapeutic window, xenograft models, toxicity
SDG: Good health and well-being

Open Access status: closed

Funder: Deutsche Forschungsgemeinschaft
OpenAlex ID: W2285196165
FWCI: 1.937
Cites: 38
Cited by: 101
Related to: 9
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security